Previous Close | 124.73 |
1-Year Change | -17.68% |
6-Months Change | -27.46% |
3-Months Change | -18.91% |
Moving Avg (50d) | 141.09 |
Moving Avg (200d) | 157.32 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 6.97M |
Beta (3-Years) | 1.44 |
Revenue Growth (ttm) | -17.41% |
Net Profit Margin (ttm) | -0.32% |
Return On Assets (ttm) | -0.07% |
EPS (ttm) | -37.07 |
PE Ratio (ttm) | -3.36 |
Dividend Yield | % |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Health Care Supplies |
Country: | United States |
Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of February 2014, Repligen employed 116 people, about 50% of these based in Sweden. Wikipedia